Lee Goldberg, MBA

In an effort to minimize the cost curve, payers have been adjusting their utilization management policies, spurred by the approval of several costly new hepatitis C medications.

With the recent approval of new hepatitis C treatments, payers are increasingly concerned with controlling costs in this category through policies that may affect treatment decisions.